Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation

BACKGROUND AND OBJECTIVES: Rivaroxaban is noninferior to warfarin for preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is associated with a lower rate of intracranial hemorrhage (ICH). We assessed the cost-effectiveness of rivaroxaban compared to adjuste...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyunmee, Kim, Hyeongsoo, Cho, Seong-Kyung, Kim, Jin-Bae, Joung, Boyoung, Kim, Changsoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393322/
https://www.ncbi.nlm.nih.gov/pubmed/30468041
http://dx.doi.org/10.4070/kcj.2018.0220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393322/
https://www.ncbi.nlm.nih.gov/pubmed/30468041
http://dx.doi.org/10.4070/kcj.2018.0220

Ejemplares similares